These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 34952201)

  • 1. PHLDB2 Mediates Cetuximab Resistance via Interacting With EGFR in Latent Metastasis of Colorectal Cancer.
    Luo M; Huang Z; Yang X; Chen Y; Jiang J; Zhang L; Zhou L; Qin S; Jin P; Fu S; Peng L; Li B; Fang Y; Pu W; Gong Y; Liu Y; Ren Z; Liu QL; Wang C; Xiao F; He D; Zhang H; Li C; Xu H; Dai L; Peng Y; Zhou ZG; Huang C; Chen HN
    Cell Mol Gastroenterol Hepatol; 2022; 13(4):1223-1242. PubMed ID: 34952201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Forkhead box K2 promotes human colorectal cancer metastasis by upregulating ZEB1 and EGFR.
    Du F; Qiao C; Li X; Chen Z; Liu H; Wu S; Hu S; Qiu Z; Qian M; Tian D; Wu K; Fan D; Nie Y; Xia L
    Theranostics; 2019; 9(13):3879-3902. PubMed ID: 31281520
    [No Abstract]   [Full Text] [Related]  

  • 3. Terminal α2,6-sialylation of epidermal growth factor receptor modulates antibody therapy response of colorectal cancer cells.
    Rodrigues JG; Duarte HO; Gomes C; Balmaña M; Martins ÁM; Hensbergen PJ; de Ru AH; Lima J; Albergaria A; van Veelen PA; Wuhrer M; Gomes J; Reis CA
    Cell Oncol (Dordr); 2021 Aug; 44(4):835-850. PubMed ID: 33847896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sonic hedgehog pathway activation is associated with cetuximab resistance and EPHB3 receptor induction in colorectal cancer.
    Park SH; Jo MJ; Kim BR; Jeong YA; Na YJ; Kim JL; Jeong S; Yun HK; Kim DY; Kim BG; Kang SH; Oh SC; Lee DH
    Theranostics; 2019; 9(8):2235-2251. PubMed ID: 31149041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive and prognostic implications of 4E-BP1, Beclin-1, and LC3 for cetuximab treatment combined with chemotherapy in advanced colorectal cancer with wild-type KRAS: Analysis from real-world data.
    Guo GF; Wang YX; Zhang YJ; Chen XX; Lu JB; Wang HH; Jiang C; Qiu HQ; Xia LP
    World J Gastroenterol; 2019 Apr; 25(15):1840-1853. PubMed ID: 31057298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab.
    Lee SK; Cho YH; Cha PH; Yoon JS; Ro EJ; Jeong WJ; Park J; Kim H; Il Kim T; Min DS; Han G; Choi KY
    Exp Mol Med; 2018 Nov; 50(11):1-12. PubMed ID: 30459318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
    Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL
    Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
    Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
    Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.
    Pentheroudakis G; Kotoula V; De Roock W; Kouvatseas G; Papakostas P; Makatsoris T; Papamichael D; Xanthakis I; Sgouros J; Televantou D; Kafiri G; Tsamandas AC; Razis E; Galani E; Bafaloukos D; Efstratiou I; Bompolaki I; Pectasides D; Pavlidis N; Tejpar S; Fountzilas G
    BMC Cancer; 2013 Feb; 13():49. PubMed ID: 23374602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer.
    Martini G; Cardone C; Vitiello PP; Belli V; Napolitano S; Troiani T; Ciardiello D; Della Corte CM; Morgillo F; Matrone N; Sforza V; Papaccio G; Desiderio V; Paul MC; Moreno-Viedma V; Normanno N; Rachiglio AM; Tirino V; Maiello E; Latiano TP; Rizzi D; Signoriello G; Sibilia M; Ciardiello F; Martinelli E
    Mol Cancer Ther; 2019 Apr; 18(4):845-855. PubMed ID: 30824612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-302a Inhibits Metastasis and Cetuximab Resistance in Colorectal Cancer by Targeting NFIB and CD44.
    Sun L; Fang Y; Wang X; Han Y; Du F; Li C; Hu H; Liu H; Liu Q; Wang J; Liang J; Chen P; Yang H; Nie Y; Wu K; Fan D; Coffey RJ; Lu Y; Zhao X; Wang X
    Theranostics; 2019; 9(26):8409-8425. PubMed ID: 31754405
    [No Abstract]   [Full Text] [Related]  

  • 12. ErbB4/KITENIN-Mediated Signaling is Activated in Cetuximab-Resistant Colorectal Cancer Cells.
    Park SY; Yang Y; Zhou R; Jung SC; Bae WK; Chung IJ; Kim KK; Kim H
    J Nanosci Nanotechnol; 2019 Feb; 19(2):1166-1171. PubMed ID: 30360226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequency of S492R mutations in the epidermal growth factor receptor: analysis of plasma DNA from patients with metastatic colorectal cancer treated with panitumumab or cetuximab monotherapy.
    Price T; Ang A; Boedigheimer M; Kim TW; Li J; Cascinu S; Ruff P; Satya Suresh A; Thomas A; Tjulandin S; Peeters M
    Cancer Biol Ther; 2020 Oct; 21(10):891-898. PubMed ID: 33026965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IGF2BP3 promotes the progression of colorectal cancer and mediates cetuximab resistance by stabilizing EGFR mRNA in an m
    Chen LJ; Liu HY; Xiao ZY; Qiu T; Zhang D; Zhang LJ; Han FY; Chen GJ; Xu XM; Zhu JH; Ding YQ; Wang SY; Ye YP; Jiao HL
    Cell Death Dis; 2023 Sep; 14(9):581. PubMed ID: 37658049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal growth factor receptor-targeted therapy in colorectal cancer.
    Xu W; Jing H; Zhang F
    Front Biosci (Landmark Ed); 2016 Jan; 21(2):410-8. PubMed ID: 26709782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ATM mutations and E-cadherin expression define sensitivity to EGFR-targeted therapy in colorectal cancer.
    Geißler AL; Geißler M; Kottmann D; Lutz L; Fichter CD; Fritsch R; Weddeling B; Makowiec F; Werner M; Lassmann S
    Oncotarget; 2017 Mar; 8(10):17164-17190. PubMed ID: 28199979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A module of inflammatory cytokines defines resistance of colorectal cancer to EGFR inhibitors.
    Gelfo V; Rodia MT; Pucci M; Dall'Ora M; Santi S; Solmi R; Roth L; Lindzen M; Bonafè M; Bertotti A; Caramelli E; Lollini PL; Trusolino L; Yarden Y; D'Uva G; Lauriola M
    Oncotarget; 2016 Nov; 7(44):72167-72183. PubMed ID: 27708224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combinational treatment with microRNA‑133b and cetuximab has increased inhibitory effects on the growth and invasion of colorectal cancer cells by regulating EGFR.
    Zhou J; Lv L; Lin C; Hu G; Guo Y; Wu M; Tian B; Li X
    Mol Med Rep; 2015 Oct; 12(4):5407-14. PubMed ID: 26151111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment dilemmas of cetuximab combined with chemotherapy for metastatic colorectal cancer.
    Wen F; Li Q
    World J Gastroenterol; 2016 Jun; 22(23):5332-41. PubMed ID: 27340349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Whole Transcriptome Analysis Identifies TNS4 as a Key Effector of Cetuximab and a Regulator of the Oncogenic Activity of KRAS Mutant Colorectal Cancer Cell Lines.
    Kim S; Kim N; Kang K; Kim W; Won J; Cho J
    Cells; 2019 Aug; 8(8):. PubMed ID: 31409052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.